Adherex boosted by GlaxoSmithKline deal
According to the terms of their agreement, Adherex will license and develop GSK’s cancer compound, eniluracil. The London-based drugmaker will retain an option to reacquire the rights to
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.